Pulse Biosciences, Inc. Payments to Acquire Debt Securities, Available-for-sale
Pulse Biosciences, Inc. (PLSE) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-03-31
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-12-31 was $3.51M, a 29.99% decline year-over-year.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-09-30 was $22.51M, a 25.66% increase year-over-year.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-03-31 was $3.01M, a 93.20% decline year-over-year.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $0.00.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $29.02M, a 62.79% decline from fiscal 2019.
- Pulse Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $77.99M, a 93.55% increase from fiscal 2018.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $26.02M derived: sum of 2 quarters · filed 2023-03-31 | $26.02M derived: sum of 3 quarters · filed 2023-03-31 | $29.02M 10-K · filed 2023-03-31 |
| 2020-09-30 | $22.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $22.51M derived: sum of 2 quarters · filed 2021-11-15 | $25.52M 10-Q · filed 2021-11-15 | $30.53M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.01M 10-Q · filed 2021-08-09 | $8.02M derived: sum of 3 quarters · filed 2022-03-31 | $25.93M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-03-31 | $3.01M 10-Q · filed 2021-05-10 | $8.02M derived: sum of 2 quarters · filed 2022-03-31 | $25.93M derived: sum of 3 quarters · filed 2022-03-31 | $36.81M derived: sum of 4 quarters · filed 2022-03-31 |
| 2019-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $22.93M derived: sum of 2 quarters · filed 2022-03-31 | $33.81M derived: sum of 3 quarters · filed 2022-03-31 | $77.99M 10-K · filed 2022-03-31 |
| 2019-09-30 | $17.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $28.80M derived: sum of 2 quarters · filed 2020-11-09 | $72.98M 10-Q · filed 2020-11-09 | $73.48M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $10.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $55.07M 10-Q · filed 2020-08-10 | $55.57M derived: sum of 3 quarters · filed 2021-03-12 | $66.25M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $44.19M 10-Q · filed 2020-05-11 | $44.68M derived: sum of 2 quarters · filed 2021-03-12 | $55.37M derived: sum of 3 quarters · filed 2021-03-12 | $65.33M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $11.19M derived: sum of 2 quarters · filed 2021-03-12 | $21.14M derived: sum of 3 quarters · filed 2021-03-12 | $40.30M 10-K · filed 2021-03-12 |
| 2018-09-30 | $10.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $20.64M derived: sum of 2 quarters · filed 2019-11-07 | $39.80M 10-Q · filed 2019-11-07 | $72.03M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $9.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $29.11M 10-Q · filed 2019-08-08 | $61.34M derived: sum of 3 quarters · filed 2020-03-16 | $61.34M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $19.16M 10-Q · filed 2019-05-03 | $51.39M derived: sum of 2 quarters · filed 2020-03-16 | $51.39M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $32.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $32.23M derived: sum of 2 quarters · filed 2020-03-16 | $43.59M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $11.36M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $11.36M 10-Q · filed 2018-07-31 | |||
| 2016-12-31 | $19.07M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |